Morgan Stanley Glycomimetics Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Glycomimetics Inc stock. As of the latest transaction made, Morgan Stanley holds 5,176 shares of GLYC stock, worth $1,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,176

Previous 5,176 -0.0%

Holding current value

$1,397

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.24 - $3.04 $23,498 - $297,652	-97,912 Reduced 94.98%	5,176 $1,000
Q2 2024 Aug 14, 2024	SELL	$0.24 - $3.04 $23,498 - $297,652	-97,912 Reduced 94.98%	5,176 $1,000
Q1 2024 Oct 17, 2024	BUY	$2.55 - $3.49 $249,675 - $341,712	97,912 Added 1891.65%	103,088 $309,000
Q1 2024 Aug 16, 2024	BUY	$2.55 - $3.49 $174,871 - $239,333	68,577 Added 198.71%	103,088 $309,000
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $174,871 - $239,333	68,577 Added 198.71%	103,088 $309,000
Q4 2023 Aug 16, 2024	BUY	$1.13 - $2.54 $33,148 - $74,510	29,335 Added 566.75%	34,511 $81,000
Q4 2023 Feb 13, 2024	SELL	$1.13 - $2.54 $6,637 - $14,919	-5,874 Reduced 14.55%	34,511 $81,000
Q3 2023 Nov 15, 2023	SELL	$1.29 - $1.73 $74,234 - $99,554	-57,546 Reduced 58.76%	40,385 $60,000
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $83,307 - $143,205	-68,849 Reduced 41.28%	97,931 $170,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $188,047 - $609,273	150,438 Added 920.56%	166,780 $210,000
Q4 2022 Feb 14, 2023	SELL	$0.57 - $3.03 $15,554 - $82,682	-27,288 Reduced 62.54%	16,342 $49,000
Q3 2022 Nov 14, 2022	BUY	$0.55 - $0.9 $5 - $9	10 Added 0.02%	43,630 $24,000
Q2 2022 Oct 27, 2022	SELL	$0.54 - $1.15 $17 - $36	-32 Reduced 0.07%	43,620 $26,000
Q2 2022 Aug 15, 2022	SELL	$0.54 - $1.15 $17 - $36	-32 Reduced 0.07%	43,620 $26,000
Q1 2022 Oct 27, 2022	BUY	$1.0 - $1.58 $32 - $50	32 Added 0.07%	43,652 $50,000
Q1 2022 May 13, 2022	SELL	$1.0 - $1.58 $9,503 - $15,014	-9,503 Reduced 17.88%	43,652 $50,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $21,267 - $31,605	-14,769 Reduced 21.74%	53,155 $76,000
Q3 2021 Nov 15, 2021	BUY	$1.8 - $2.39 $122,263 - $162,338	67,924 New	67,924 $148,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.7M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account